While the DAPA-CKD trial did not include any patients receiving the nonsteroidal MR antagonist finerenone, a post-hoc analysis of the FIDELIO-DKD trial further demonstrated that the impact of finerenone on CV and renal outcomes was independent of SGLT2 inhibitor use [56]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.